James Martin Nolan, Iii

Title: Innovations of James Martin Nolan, III

Introduction

James Martin Nolan, III is an accomplished inventor based in Boston, MA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of aryl hydrocarbon receptor (AHR) inhibitors. With a total of two patents to his name, Nolan's work is paving the way for advancements in medical treatments.

Latest Patents

Nolan's latest patents include innovative formulations of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine. The first patent provides freebase and salt forms of this compound, which act as inhibitors of AHR. These formulations are useful for treating various conditions where the AHR is implicated. The second patent focuses on solid forms of the same compound, specifically the maleate form, which also serves as an AHR inhibitor.

Career Highlights

Nolan is currently employed at Ikena Oncology, Inc., where he continues to innovate in the field of oncology. His work is characterized by a commitment to developing effective treatments that target specific biological pathways.

Collaborations

Some of his notable coworkers include Alfredo C. Castro and Sarah Jean Bethune, who contribute to the collaborative environment at Ikena Oncology, Inc. Their combined expertise enhances the research and development efforts within the company.

Conclusion

James Martin Nolan, III is a notable inventor whose work in AHR inhibitors is making a significant impact in the pharmaceutical industry. His contributions are essential for the advancement of targeted therapies in oncology.